TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Guan, Xiaoxiang ^a   Liao, Zhongxin ^a   Ma, Hongxia ^a   Qian, Ji ^a   Liu, Zhensheng ^a   Yuan, Xianglin ^b   Gomez, Daniel ^a   Komaki, Ritsuko ^a   Wang, Li E ^a   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Non small cell lung cancer; Polymorphism; Survival; Tnf ; Tnfrsf1b

Indexed keywords

PLATINUM; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TNFRSF1B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TNFRSF1B GENE; AGED; CHEMORADIOTHERAPY; GENETIC POLYMORPHISM; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053980947     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-447     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-917. 10.1002/ijc.25516, 21351269.
2. Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res 2005, 11:5057s-5062s. 10.1158/1078-0432.CCR-05-9012, 16000614.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
4. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001, 71:1759-1764. 10.1016/S0003-4975(00)02609-6, 11426744.
5. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756. 10.1038/nri1184, 12949498.
6. Boldrini L, Calcinai A, Samaritani E, Pistolesi F, Mussi A, Lucchi M, Angeletti CA, Basolo F, Fontanini G. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer 2000, 83:480-486. 10.1054/bjoc.2000.1345, 2374649, 10945495.
7. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Melfi F, Mussi A, Basolo F, Fontanini G. Tumour necrosis factor-alpha: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. Int J Mol Med 2006, 17:887-892.
8. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994, 56:777-782. 10.1002/ijc.2910560603, 8119765.
9. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993, 91:2194-2206. 10.1172/JCI116446, 288222, 8387543.
10. Tran TA, Kallakury BV, Ambros RA, Ross JS. Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma. Cancer 1998, 83:276-282. 10.1002/(SICI)1097-0142(19980715)83:2<276::AID-CNCR11>3.0.CO;2-Q, 9669810.
11. Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, Endo I, Kunisaki C, Suzuki H, Hayasizaki Y, et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer 2006, 119:406-413. 10.1002/ijc.21843, 16477629.
12. Su C, Zhou C, Zhou S, Xu J. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Med Oncol 2010,
13. Rube CE, Wilfert F, Uthe D, Schmid KW, Knoop R, Willich N, Schuck A, Rube C. Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol 2002, 64:177-187. 10.1016/S0167-8140(02)00077-4, 12242128.
14. Zhang M, Qian J, Xing X, Kong FM, Zhao L, Chen M, Lawrence TS. Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res 2008, 14:1868-1876. 10.1158/1078-0432.CCR-07-1894, 18347190.
15. Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001, 62:1191-1199. 10.1016/S0198-8859(01)00322-6, 11704281.
16. Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, Shimosegawa T, Toyota T. Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene. Gastroenterology 1999, 117:1062-1068. 10.1016/S0016-5085(99)70390-2, 10535868.
17. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997, 349:1912-1913. 10.1016/S0140-6736(05)63910-4, 9217780.
18. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199. 10.1073/pnas.94.7.3195, 20345, 9096369.
19. Beltinger CP, White PS, Maris JM, Sulman EP, Jensen SJ, LePaslier D, Stallard BJ, Goeddel DV, de Sauvage FJ, Brodeur GM. Physical mapping and genomic structure of the human TNFR2 gene. Genomics 1996, 35:94-100. 10.1006/geno.1996.0327, 8661109.
20. Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y, Otsuka T, Sawabe T, Harashima S, Nagasawa K, et al. Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 2001, 44:2819-2827. 10.1002/1529-0131(200112)44:12<2819::AID-ART469>3.0.CO;2-2, 11762942.
21. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms?. Genes Immun 2004, 5:315-329. 10.1038/sj.gene.6364055, 14973548.
22. Gaudet MM, Egan KM, Lissowska J, Newcomb PA, Brinton LA, Titus-Ernstoff L, Yeager M, Chanock S, Welch R, Peplonska B, et al. Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. Hum Genet 2007, 121:483-490. 10.1007/s00439-006-0315-x, 17216494.
23. Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech 2000, 50:216-228. 10.1002/1097-0029(20000801)50:3<216::AID-JEMT5>3.0.CO;2-Q, 10891887.
24. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998, 77:2246-2251. 10.1038/bjc.1998.373, 2150409, 9649140.
25. Shih CM, Lee YL, Chiou HL, Chen W, Chang GC, Chou MC, Lin LY. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 2006, 52:15-20. 10.1016/j.lungcan.2005.11.011, 16476505.
26. Mestiri S, Bouaouina N, Ben Ahmed S, Chouchane L. A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma. Cytokine 2005, 30:182-187. 10.1016/j.cyto.2005.01.007, 15863392.
27. Stankovic MM, Nestorovic AR, Tomovic AM, Petrovic-Stanojevic ND, Andjelic-Jelic MS, Dopudja-Pantic VB, Nagorni-Obradovic Lj M, Mitic-Milikic MM, Radojkovic DP. TNF-alpha-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer. Neoplasma 2009, 56:348-352. 10.4149/neo_2009_04_348, 19469656.
28. Ahirwar DK, Mandhani A, Dharaskar A, Kesarwani P, Mittal RD. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy. BJU Int 2009, 104:867-873. 10.1111/j.1464-410X.2009.08549.x, 19338536.
29. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun Wee J, Kim WJ. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005, 65:70-75. 10.1016/j.urology.2004.08.005, 15667866.
30. Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI, Kim MS, Paik KH. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 2001, 166:41-46. 10.1016/S0304-3835(01)00438-4, 11295285.
31. Yapijakis C, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Vassiliou S, Avgoustidis D, Neukam FW, Patsouris E, Vairaktaris E. Association of polymorphisms in Tumor Necrosis Factor Alpha and Beta genes with increased risk for oral cancer. Anticancer Res 2009, 29:2379-2386.
32. Gupta R, Sharma SC, Das SN. Association of TNF-alpha and TNFR1 promoters and 3' UTR region of TNFR2 gene polymorphisms with genetic susceptibility to tobacco-related oral carcinoma in Asian Indians. Oral Oncol 2008, 44:455-463. 10.1016/j.oraloncology.2007.06.003, 18206417.
33. Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, Castro Alves C, Campos ML, Van Doorn LJ, Caldas C, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003, 125:364-371. 10.1016/S0016-5085(03)00899-0, 12891537.
34. Fang F, Yao L, Yu XJ, Yu L, Wu Q. TNFalpha -308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls. Breast Cancer Res Treat 122:267-271.
35. Jeong P, Kim EJ, Kim EG, Byun SS, Kim CS, Kim WJ. Association of bladder tumors and GA genotype of -308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression. Urology 2004, 64:1052-1056. 10.1016/j.urology.2004.06.018, 15533517.
36. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Chouchane L. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 2001, 91:672-678. 10.1002/1097-0142(20010215)91:4<672::AID-CNCR1050>3.0.CO;2-J, 11241233.
37. Kladny J, Suchy J, Klujszo-Grabowska E, Kacperski T, Scott RJ, Kurzawski G, Lubinski J. Clinical characteristics of tumors derived from colorectal cancer patients who harbor the tumor necrosis factor alpha-1031T/T and NOD2 3020insC polymorphism. Cancer Epidemiol 2009, 33:161-163. 10.1016/j.canep.2009.06.004, 19679065.
38. Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009, 27:3370-3378. 10.1200/JCO.2008.20.6763, 19380441.
39. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009, 37:W600-605. 10.1093/nar/gkp290, 2703930, 19417063.
40. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002, 87:13-15.
41. Das SN, Baniasadi V, Kapuria V. Association of -308 TNF-alpha promoter polymorphism with type 1 diabetes in North Indians. Int J Immunogenet 2006, 33:411-416. 10.1111/j.1744-313X.2006.00632.x, 17117950.
42. Glas J, Torok HP, Schneider A, Brunnler G, Kopp R, Albert ED, Stolte M, Folwaczny C. Allele 2 of the interleukin-1 receptor antagonist gene is associated with early gastric cancer. J Clin Oncol 2004, 22:4746-4752. 10.1200/JCO.2004.03.034, 15570075.
43. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer 2008, 7:331-337. 10.3816/CCC.2008.n.044, 18794066.
44. Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, D'Alo F, Guidi F, Greco M, Pierconti F, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007, 18:1376-1381. 10.1093/annonc/mdm132, 17496310.
45. Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 2004, 31:167-173. 10.1111/j.1365-2370.2004.00462.x, 15265021.
46. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993, 268:18542-18548.
47. Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003, 76:1742-1749. 10.1097/01.TP.0000092496.05951.D5, 14688526.
48. Till A, Rosenstiel P, Krippner-Heidenreich A, Mascheretti-Croucher S, Croucher PJ, Schafer H, Scheurich P, Seegert D, Schreiber S. The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem 2005, 280:5994-6004.
49. Kuwahara A, Yamamori M, Fujita M, Okuno T, Tamura T, Kadoyama K, Okamura N, Nakamura T, Sakaeda T. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2010, 29:100. 10.1186/1756-9966-29-100, 2915971, 20646319.
50. Sainz J, Pérez E, Hassan L, Moratalla A, Romero A, Collado MD, Jurado M. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007, 68:41-50. 10.1016/j.humimm.2006.10.011, 17207711.